What Psilocybin and MDMA Are Really Doing to the Human Body — and Why Every Leader Needs to Pay Attention
Seven men die by suicide in Australia - every day.
Men account for three in every four suicides — a ratio that has held steady since 1983. Suicide is the leading cause of death for Australian men aged 25 to 44. Not cancer. Not heart disease. Suicide.
The working-age male cohort hit a record high number of suicides in 2024.
Now here’s a statistic that stopped me (a divorcee) cold when I first encountered it. Compared to divorced women, divorced men are nine times more likely to die by suicide. Nine times. That is not a rounding error. That is a civilisational failure to support men through one of life’s most destabilising transitions.
And the pattern doesn’t stop at suicide. 93% of Australia’s prison population is male. 56% of homeless Australians are male. Approximately half of males with suicidal thoughts have never accessed mental health services. Not because services don’t exist. Because the dominant model — sit across from a therapist, take a daily pill, wait six weeks — is failing a significant cohort of men who won’t, or can’t, engage with it.
These aren’t separate problems. They are symptoms of the same underlying crisis: men carrying unprocessed trauma and psychological pain through lives the system was never designed to heal.
I write this as a futurist who has spent two decades tracking the signals that matter before they reach the boardroom agenda. I also write this as a survivor of childhood and adult trauma and abuse. Which means this conversation has never been abstract to me.
So let me ask you the question I put to a room full of senior leaders recently:
So when I look at psilocybin and MDMA, I’m not looking at a longevity experiment for biohackers. I’m looking at a potential answer to one of the most stubborn crises of our time.
And here is what makes this story genuinely extraordinary.
Most interventions work on one dimension. Statins target your cardiovascular system. Antidepressants target serotonin. Exercise is good for your body and moderately good for your mood. Therapy is good for your mind and moderately good for your resilience.
Psilocybin appears to work on cellular biology and psychological wellbeing at the same time — through related but distinct mechanisms. The same compound producing 50%+ remission rates in treatment-resistant depression and 71% lasting relief in PTSD is also, in a July 2025 study out of Emory University and Baylor College of Medicine, extending the lifespan of human cells by up to 57%.
That’s not coincidence. Researchers now suspect that psilocybin’s effects on ageing and its effects on mental health may both trace back to the same underlying process: reducing inflammation, increasing neuroplasticity, and upregulating the cellular repair systems that decline with both age and chronic psychological stress.
That’s the question that put this research on my radar. And the one I now put to every leadership audience I work with.
I grew up in Sweden. And as a Swede steeped in Nordic culture, I have a particular relationship with this story.
Long before clinical trials, before pharmaceutical patents, before the War on Drugs, Norse cultures had a sophisticated and intentional relationship with psychoactive plants and fungi. Dried mushrooms, including Amanita muscaria, have been found in Viking graves across Sweden and Norway, suggesting ceremonial and ritual use. The iconic red-and-white toadstool appears in Norse artwork and is believed by scholars to have been used in healing ceremonies, spiritual rituals, and altered states of consciousness. Every year in autumn my parents, my grandparents and my brother and I foraged for mushrooms, and children's tales often featured mushrooms - both magic and non-magic ones.
To be honest about the historical record: the exact nature of Viking mushroom use is contested among academics. Whether berserker warriors specifically used psychoactive fungi, or whether it was henbane or other plants, remains debated. What the archaeological and ethnobotanical evidence does consistently confirm is that Norse cultures treated these substances as medicine, ceremony, and consciousness technology. Not as something to criminalise.
And they weren’t alone. From Mesoamerican healers to indigenous communities across Africa, Asia, and the Pacific, psychoactive plants and fungi have been used for trauma recovery, spiritual practice, and community healing for millennia. Thousands of years of accumulated human wisdom wasn’t lost. It was criminalised.
The War on Drugs didn’t discover that these substances were dangerous. It decided they were inconvenient.
The science emerging now isn’t discovering something new. It’s catching up with something ancient. And as a futurist, I recognise this pattern: the most disruptive breakthroughs often look backwards before they look forwards.
Researchers at Baylor College of Medicine found that psilocybin extended cellular lifespan by up to 57%, depending on dosage. The active metabolite (psilocin) delayed cellular senescence, preserved telomere length, reduced oxidative stress, and increased SIRT1 expression — a gene central to cellular metabolism, DNA repair, and longevity.
In mouse studies, female mice aged 19 months (roughly equivalent to 60–65 human years) received monthly psilocybin doses. After 10 months, 80% of treated mice were still alive, compared to 50% of the control group. Treated mice also showed visibly healthier fur and colouring — markers of slower biological ageing.
I want to be upfront about the limits here. These are cell and mouse studies. As longevity researcher Peter Attia has pointed out, the telomere findings need further human validation before we can draw clinical conclusions. The researchers themselves are clear on this. The science is promising, not yet proven for humans. But in my experience of tracking emerging signals, this is exactly the pattern that precedes rapid acceleration.
Bryan Johnson, the biohacker spending roughly $2 million a year trying not to age, has now added psilocybin to his protocol. In November 2025, he took 4.67 grams of psilocybin mushrooms under medical supervision, in a legal setting, with a professional facilitator. He tracked 249 biomarkers before and after.
His results were striking. Systemic inflammation dropped more than 35% — from elite to undetectable. Brain plasticity increased measurably. His default mode network showed what researchers call an entropic brain pattern, associated with increased cognitive flexibility, creativity, and openness.
His conclusion: “I think magic mushrooms are a longevity therapy. Psilocybin offers unique longevity effects that complement the best-performing therapies I’ve done to date. Even though many of my biomarkers are already in the 99th percentile, psilocybin still showed multi-system improvements. Something other therapies have not accomplished.”
For someone with $2 million worth of data points, that’s a meaningful statement.
Psilocybin therapy has shown sustained remission in over 50% of depression patients at six months. MDMA-assisted psychotherapy has produced lasting symptom relief in 71% of veterans and first responders with PTSD at 12 months. For context, conventional antidepressants produce remission in roughly 30–40% of patients — and the figures are far worse for treatment-resistant cases. Childhood trauma sits at the severe end of that spectrum.
Johns Hopkins now has a dedicated Centre for Psychedelic and Consciousness Research, investigating psilocybin across opioid addiction, Alzheimer’s disease, PTSD, anorexia nervosa, and alcohol use disorder. More than 150 clinical studies have been completed or are underway globally.
Australia made a landmark regulatory decision in July 2023, becoming the first nation to formally approve both psilocybin and MDMA for therapeutic use under authorised psychiatrists. In the United States, the FDA rejected MDMA-assisted therapy for PTSD in August 2024, citing insufficient evidence — though psilocybin for treatment-resistant depression is widely considered next in line for FDA review. The UK, Canada, and several European jurisdictions are actively progressing their own frameworks.
This is not fringe science anymore. It’s frontier medicine.
Fair question.
My job is to identify the signals that will reshape industries, organisations, and human experience before they become obvious. Most of those signals are technological. But the numbers at the top of this piece — seven men a day, nine times the suicide risk for divorced men, half of men in crisis who never seek help — are not abstract social statistics. They describe the real, invisible load that leaders carry into every strategic decision, every high-stakes moment, every room I work in.
Here’s the frame I bring that neither a clinician nor a policy advocate can offer: I look at this through the lens of what it costs organisations not to take it seriously, and what becomes possible when they do.
The World Health Organisation estimates depression and anxiety cost the global economy US$1 trillion annually in lost productivity. In Australia alone, untreated mental illness costs employers approximately $10.9 billion per year through absenteeism, presenteeism, and turnover.
A senior leader who moves from treatment-resistant depression or unresolved trauma into sustained clinical remission doesn’t just feel better. They think more clearly, lead more effectively, make better decisions, and stay. The retention and productivity implications alone are significant.
There’s also a growing body of research showing that therapeutic psychedelic experiences produce measurable increases in cognitive flexibility — the ability to shift perspective, break habitual thinking patterns, and generate novel solutions. These are precisely the capacities organisations spend hundreds of thousands of dollars trying to develop through leadership programs, often with modest results.
Einstein observed — in words widely quoted if variously attributed — that “no problem can be solved from the same level of consciousness that created it.”
We are living through what complexity theorists call wicked problems: climate disruption, AI displacement, geopolitical fracturing, systemic inequality. Problems that are genuinely unsolvable using the same mental models and habitual thinking patterns that generated them.
And yet the dominant model of leadership consciousness has barely evolved. We invest enormously in technical and strategic capability. We invest almost nothing in expanding the depth of awareness that leaders bring to their decisions.
What the research on psilocybin-assisted therapy consistently shows, beyond symptom reduction, is a measurable shift in how people relate to themselves, to others, and to their circumstances. Increased openness. Reduced ego rigidity. Greater capacity for empathy, long-term thinking, and genuine systemic perspective. These are not soft outcomes. They are exactly the qualities that distinguish adaptive leaders from brittle ones in a period of rapid, compounding change.
1. What is your organisation’s position on psychedelic-assisted therapy?
In Australia, this is no longer hypothetical. Employees may already be accessing these treatments legally under TGA approval. Does your HR policy account for this? Does your occupational health framework reflect the current regulatory reality?
2. How are you thinking about longevity as a strategic asset?
If psilocybin’s cellular effects are validated in human studies, the performance window of your most experienced people may extend in ways that fundamentally reshape workforce planning, retirement assumptions, and institutional knowledge retention.
3. Are you developing the quality of consciousness your leadership challenges actually require?
Australia is ahead on regulation. The UK is moving. The FDA has granted psilocybin Breakthrough Therapy designation for treatment-resistant depression. The window for developing a proactive, informed position — rather than reacting when it arrives — is open right now.
What is psilocybin and why should business leaders pay attention?
Psilocybin is the naturally occurring psychoactive compound found in certain mushroom species. Long associated with counterculture, it is now the subject of serious clinical investigation across depression, PTSD, addiction, Alzheimer’s disease, and cellular ageing. For leaders, it matters because its therapeutic applications address the mental health and performance challenges most affecting high-performing teams, and its longevity implications are beginning to reshape how progressive organisations think about human capital.
Is psilocybin legal in Australia?
Since July 2023, both psilocybin and MDMA have been approved by Australia’s Therapeutic Goods Administration for therapeutic use under authorised psychiatrists in controlled clinical settings. Recreational use remains illegal. This article discusses therapeutic and research contexts only, and nothing here constitutes medical or legal advice.
What did the 2025 Emory and Baylor longevity study find?
Published in NPJ Aging (Kato et al., July 2025), the study found that psilocin extended the cellular lifespan of human cells by up to 57% at higher doses, and improved survival rates in aged mice from 50% to 80% over 10 months. The researchers described psilocybin as a potential geroprotective agent. Human validation studies are required before clinical longevity applications can be confirmed.
What did Bryan Johnson’s psilocybin experiment show?
In November 2025, Bryan Johnson conducted what he described as the most quantified psychedelic experiment ever undertaken, tracking 249 biomarkers across two high-dose psilocybin sessions. Systemic inflammation dropped more than 35% to undetectable levels. Brain plasticity increased measurably. He concluded that psilocybin is a longevity therapy that produced multi-system improvements other therapies had not achieved, even at his already elite biomarker baseline.
Why are men so disproportionately affected by poor mental health outcomes?
Men are less likely to seek help, less likely to have built the social support structures needed to weather crisis, and more likely to face the specific risk factors — relationship breakdown, financial stress, isolation — most strongly linked to suicide. Divorced men are nine times more likely to die by suicide than divorced women, a disparity that dwarves even the general male-female gap in suicide rates. These are systemic failures, not individual weaknesses. They are exactly why therapeutic interventions that don’t rely solely on traditional help-seeking behaviours — like supervised psychedelic-assisted therapy — matter so much.
What does conscious leadership have to do with psychedelic therapy?
Psilocybin-assisted therapy consistently produces measurable increases in psychological openness, reduced ego rigidity, enhanced empathy, and greater capacity for long-term, systemic thinking. These are the qualities leadership development programs seek to cultivate, often at great cost and with limited results. The connection to conscious leadership is not metaphorical. It is neurological.
How do I book Anders Sorman-Nilsson as a keynote speaker on the future of human performance?
Anders speaks on the convergence of human biology, technology, and the future of work for leadership teams, conference audiences, and corporate offsites globally. To discuss your event and check availability, contact Thinque at anders@thinque.com or via the enquiry form at anderssorman-nilsson.com.
All factual claims are linked to primary or peer-reviewed sources. Where historical evidence is speculative (Norse mushroom use), this is acknowledged explicitly in the text.
Note: The link between Norse cultures and psilocybin specifically is historically speculative. Archaeological evidence confirms psychoactive mushrooms and plants in Norse grave sites; the precise compounds and ritual uses remain debated among academics.
Note: This quote is widely attributed to Einstein and consistent with his documented philosophy, though its precise provenance is debated by scholars.